A Single Dose-escalation Study to Evaluate the Safety and Efficacy of Allogeneic CAR-T Targeting CD19 Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B Cell Acute Lymphoblastic Leukemia
ThisCART19, an allogeneic CAR-T therapy targeting CD19, is being developed by Fundamenta Therapeutics for the treatment of refractory or relapsed B-cell acute lymphoblastic leukemia (r/r B-ALL). The market for CAR-T therapies is expanding, particularly in hematological malignancies, with increasing demand for innovative treatments due to the high unmet need in this patient population. The competitive landscape includes established players like Novartis and Gilead, which may pose challenges in terms of market entry and pricing strategies. Diligence should focus on the safety and efficacy data emerging from this trial, as well as potential partnerships or collaborations that could enhance market access and distribution.
Indication: Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
Modality: cell therapy
Target: CD19 (molecular target for CAR-T therapy)
Sponsor: Fundamenta Therapeutics, Ltd.
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 10, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CD19 (molecular target for CAR-T therapy)
View original source fields
Condition raw: Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
Condition normalized: Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: CD19 (molecular target for CAR-T therapy)
Target normalized: CD19 (molecular target for CAR-T therapy)